Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration has granted approval for Fresenius Kabi's Kabiven and Perikabiven, which are intravenously infused solutions of lipids, dextrose, amino acids and electrolytes in three-chamber parenteral nutrition (PN) bags.
Subscribe to our email newsletter
The three-chamber PN bags help in delivering these nutrients in volumes and concentrations that meet the nutritional needs of most patients.
For patients who cannot digest or absorb sufficient nutrition through the gastrointestinal tract, PN is the intravenous administration of nutrition, which includes protein, carbohydrates, lipids (fats), electrolytes, vitamins and other trace elements.
Kabiven secured initial marketing authorization in 1999, and since then it has been used to treat about nine million patients. It is currently sold in more than 85 countries outside the US.
Fresenius Kabi USA president and CEO John Ducker said the company is happy to bring new alternatives like Kabiven and Perikabiven to US patients.
"This is especially important as many of the macro- and micro-nutrients in Kabiven and Perikabiven have been in short supply in the United States," Ducker said.
The company specializes in providing life-saving medicines and technologies for infusion, transfusion and clinical nutrition.